218
Participants
Start Date
May 28, 2019
Primary Completion Date
November 24, 2020
Study Completion Date
November 24, 2020
semaglutide
Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
Novo Nordisk Investigational Site, 's-Hertogenbosch
Novo Nordisk Investigational Site, Alkmaar
Novo Nordisk Investigational Site, Almelo
Novo Nordisk Investigational Site, Almere Stad
Novo Nordisk Investigational Site, Amersfoort
Novo Nordisk Investigational Site, Arnhem
Novo Nordisk Investigational Site, Bladel
Novo Nordisk Investigational Site, Dordrecht
Novo Nordisk Investigational Site, Eindhoven
Novo Nordisk Investigational Site, Eindhoven
Novo Nordisk Investigational Site, Emmen
Novo Nordisk Investigational Site, Enschede
Novo Nordisk Investigational Site, Gemert
Novo Nordisk Investigational Site, Groningen
Novo Nordisk Investigational Site, Heerlen
Novo Nordisk Investigational Site, Hoogeveen
Novo Nordisk Investigational Site, Leiden
Novo Nordisk Investigational Site, Montfort
Novo Nordisk Investigational Site, Nijverdal
Novo Nordisk Investigational Site, Rotterdam
Novo Nordisk Investigational Site, Sint Anthonis
Novo Nordisk Investigational Site, The Hague
Novo Nordisk Investigational Site, Utrecht
Novo Nordisk Investigational Site, Warmenhuizen
Novo Nordisk Investigational Site, Zaandam
Novo Nordisk Investigational Site, Zevenbergen
Novo Nordisk Investigational Site, Zwijndrecht
Lead Sponsor
Novo Nordisk A/S
INDUSTRY